Expert panel of 8 dermatologists from the Skin Cancer Prevention Working Group developed 6 concensus statements supporting the appropriate use of GEP testing

To improve identification of patients with cutaneous squamous cell carcinoma (SCC) at high risk for metastatic disease, the DecisionDx-SCC assay, a prognostic 40-gene expression profile (40-GEP) test, was developed and validated.

The 31-GEP accurately identified patients with stage IB-II CM at low and high risk of melanoma relapse in a prospective, multicenter study. Identifying which tumors have the highest probability of recurrence or metastasis, despite negative SLN results can aid in earlier disease detection.

Final report from a prospective study assessing the impacy of 31-GEP testing results on clinical management decisions including changes in imaging, laboratory work, and frequency of office visits. outcomes data included.

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, and the number of deaths due to cSCC is estimated to be greater than the number attributed to melanoma.

While improvements have been made to risk assessment of cutaneous squamous cell carcinoma (cSCC) patients, there is a critical need for a uniform and more precise stratification system of their care.

Over 50% of newly diagnosed cutaneous squamous cell carcinoma (cSCC) lesions occur in the head and neck (cSCC‐HN), and metastasis to nodal basins in this region further complicates surgical and adjuvant treatment.

The spatialomics approach of TissueCypher brings precision pathology to the clinic for more personalized care of patients with BE to improve outcomes.

he incidence and mortality rates of cutaneous squamous cell carcinoma (cSCC) in the Medicare population are rapidly increasing. The current national guidelines are broad and the available staging systems for stratification are inadequate to accurately guide patient management.

To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods.

The TissueCypher test may enable physicians to target EET for high-risk BE patients, while reducing unnecessary procedures in low-risk patients.

DecisionDx-Melanoma significantly stratified patient risk for RFS, DMFS, and MSS (p < 0.001) and was a significant, independent predictor of metastatic recurrence (hazard ratio: 5.38; p = 0.014).